Galectin 3C

Drug Profile

Galectin 3C

Alternative Names: Gal-3C; Galectin-3C

Latest Information Update: 02 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MandalMed
  • Developer MandalMed; Texas Tech University Health Sciences Center; University of California at San Francisco
  • Class Antifibrotics; Galectins
  • Mechanism of Action Galectin 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Breast cancer; Cancer; Lymphoma

Highest Development Phases

  • Preclinical Breast cancer
  • Research Fibrosis; Lymphoma
  • No development reported Multiple myeloma

Most Recent Events

  • 02 Aug 2016 Preclinical development is ongoing for Breast cancer in the US
  • 02 Aug 2016 Galectin 3C is available for licensing as of 02 Aug 2016. http://www.mandalmed.com/
  • 02 Aug 2016 Early research in Lymphoma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top